SEC Company Response from Transcode Therapeutics, (RNAZ) — Dec 18, 2025
Transcode Therapeutics, Inc.
Date: Dec. 18, 2025 · CIK: 0001829635 · Accession: 0001104659-25-122526
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292112
Letter
VIA EDGAR Attention: Mr. Alan Campbell Acceleration Request for Registration Statement on Form S-3 File No. 333-292112
Re: TransCode Therapeutics, Inc.
Dear Mr. Campbell:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), TransCode Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to December 22, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072.
Please contact Adam V. Johnson of Goodwin Procter LLP via telephone at (212) 459-7072 or via e-mail (AdamJohnson@goodwinlaw.com) with any questions.
Sincerely,
TRANSCODE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm December 18, 2025 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-3233 Attention: Mr. Alan Campbell Re: TransCode Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-292112 Dear Mr. Campbell: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), TransCode Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to December 22, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. Please contact Adam V. Johnson of Goodwin Procter LLP via telephone at (212) 459-7072 or via e-mail (AdamJohnson@goodwinlaw.com) with any questions. Sincerely, TRANSCODE THERAPEUTICS, INC. /s/ Philippe P. Calais Philippe P. Calais Chief Executive Officer cc: Thomas Fitzgerald, TransCode Therapeutics, Inc. Michael Bison, Goodwin Procter LLP Adam V. Johnson, Goodwin Procter LLP